Cidara Therapeutics
6310 Nancy Ridge Drive Suite 101
San Diego, CA 92121
United States
Tel: (858) 752-6170
Website: http://www.cidara.com/
Email: careers@cidara.com
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE). Cidara is also advancing a second Phase 3 trial of once-weekly rezafungin for prophylaxis against invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT) initially in Europe and Canada. In addition to its robust rezafungin clinical program, Cidara is applying its proprietary Cloudbreak® platform to develop antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases. The Cloudbreak platform is designed to discover compounds that both directly kill pathogens and direct a patient’s immune system to attack and eliminate pathogens. Cidara is headquartered in San Diego, California.
184 articles about Cidara Therapeutics
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Cidara Therapeutics and Mundipharma today shared positive topline results from their Phase III trial on the use of rezafungin for candidemia and invasive candidiasis.
-
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
12/14/2021
Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis.
-
Cidara Therapeutics Named A San Diego Metro Area Top Workplace For The Fifth Consecutive YearCidara recognized as the top-ranked biotech therapeutics company based on employee feedback
11/22/2021
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the fifth consecutive year.
-
Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results
11/10/2021
Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, reported financial results for the third quarter ended September 30, 2021 and provided an update on its corporate activities and product pipeline.
-
Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
10/13/2021
Cidara Therapeutics, Inc. announced the closing of its previously announced concurrent but separate underwritten public offerings of 17,064,511 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,225,805 shares of common stock, at a price to the public of $1.55 per share and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of $15.50 per share.
-
Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock
10/8/2021
Cidara Therapeutics, Inc. (Nasdaq: CDTX), today announced the pricing of concurrent but separate underwritten public offerings of 14,838,706 shares of its common stock at a price to the public of $1.55 per share and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of $15.50 per share.
-
Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock
10/7/2021
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it has commenced concurrent but separate underwritten public offerings of its common stock and its Series X Convertible Preferred Stock.
-
It was a busy week for clinical trial news. Here’s a look.
-
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
10/1/2021
Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious diseases, announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 169,000 shares of its common stock to ten new employees, pursuant to the Cidara Therapeutics, Inc.
-
Cidara Therapeutics to Present New Data for Rezafungin at TIMM Congress
9/29/2021
Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will present new clinical and non-clinical data in two poster presentations at the 10th Congress on Trends in Medical Mycology (TIMM) taking place in-person in Aberdeen, Scotland and virtually from October 8-11, 2021.
-
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021
9/27/2021
Cidara Therapeutics, Inc. (NASDAQ: CDTX), today announced that it will present new clinical and non-clinical data in three on-demand poster presentations, including data on rezafungin clinical safety and pharmacokinetics in people with hepatic impairment, at IDWeek taking place virtually from September 29-October 3, 2021.
-
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences in September 2021
9/7/2021
Cidara Therapeutics, Inc. announced that Jeffrey Stein, Ph.D., president and chief executive officer, will participate in two upcoming investor conferences: the H.C. Wainwright 23rd Annual Global Investment Conference and Cantor Global Healthcare Conference.
-
Cidara Therapeutics to Host Research and Development Day
9/2/2021
Cidara Therapeutics, Inc., a biotechnology company developing long-acting compounds designed to transform the standard of care for prevention and treatment of serious diseases, announced that it will host a research and development day webinar on Tuesday, September 21, 2021 from 10am to 12pm Eastern Time.
-
Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary
9/1/2021
Cidara Therapeutics, Inc. today announced the appointments of Preetam Shah, Ph.D., MBA, as chief financial officer and chief business officer, and Shane Ward as chief legal officer and corporate secretary.
-
Clinical Catch-Up: August 16-20
8/23/2021
It was another busy week in clinical trial news. Here’s a look. -
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
8/17/2021
Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Mundipharma today announced that the companies have completed recruitment of the pivotal Phase 3 ReSTORE trial evaluating the efficacy and safety of rezafungin as a potential first-line treatment for candidemia and invasive candidiasis.
-
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
8/12/2021
Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, reported financial results for the second quarter ended June 30, 2021 and provided an update on its corporate activities and product pipeline.
-
Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
8/5/2021
Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021.
-
The FDA Watch List considers drug-resistant Candida auris (C. auris) an urgent threat, drug-resistant Candida species a serious threat, and azole-resistant Aspergillus Fumigatus worth watching – especially since person-to-person transmission of drug-resistant fungi has been recently documented.